Publications by authors named "Timothy Maclachlan"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

5,433

Total Likes

374

Extended Reach

1,315,184

Social Features

101
C
CRISPR-Cas9 Editing of the and Promoters to Treat Sickle Cell Disease.
Akshay Sharma, Jaap-Jan Boelens, Maria Cancio, Jane S Hankins, Prafulla Bhad, Marjohn Azizy, Andrew Lewandowski, Xiaojun Zhao, Shripad Chitnis, Radhika Peddinti

N Engl J Med· August 2023

Videos about Article: user user

2 2 99 6 35 2

View All Article and Social Media Activity
C
Comparative assessment of the transduction efficiency and safety associated with the delivery of AAV9-GFP vector via lumbar puncture to cynomolgus macaques with and without anti-AAV9 pre-existing antibodies.
Ghiabe H Guibinga, Janet Do, Binh Chu, Yin Gu, Rie Kikkawa, Timothy MacLachlan

Mol Ther Methods Clin Dev· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Bespoke Gene Therapy Consortium: facilitating development of AAV gene therapies for rare diseases.
P J Brooks, Timothy M Miller, Frédéric Revah, Junghae Suh, Bradley R Garrison, Timothy K MacLachlan

Nat Rev Drug Discov· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regulatory Consideration for the Nonclinical Safety Assessment of Gene Therapies.
Jeffrey S Moffit, Diann L Blanset, Jessica L Lynch, Timothy K MacLachlan, Kathleen E Meyer

Hum Gene Ther· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Classic and evolving approaches to evaluating cross reactivity of mAb and mAb-like molecules - A survey of industry 2008-2019.
Timothy K MacLachlan, Shari Price, Joy Cavagnaro, Laura Andrews, Diann Blanset

Regul Toxicol Pharmacol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Industry experiences with immune-mediated findings in biotherapeutic nonclinical toxicology studies.
Timothy K MacLachlan, Sven Kronenberg, Nikki Marshall, Laura Andrews, Shawn Jay Berens

Regul Toxicol Pharmacol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nonclinical Studies that Support Viral Vector-Delivered Gene Therapies: An EFPIA Gene Therapy Working Group Perspective.
Michael W Bolt, Laurence O Whiteley, Jessica L Lynch, Brian Lauritzen, Antonio R Fernández de Henestrosa, Timothy MacLachlan

Mol Ther Methods Clin Dev· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nonclinical Safety Evaluation of scAAV8- for Treatment of Retinitis Pigmentosa.
Timothy K MacLachlan, Mark N Milton, Oliver Turner, Francis Tukov, Vivian W Choi

Mol Ther Methods Clin Dev· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Inflammation and immunogenicity limit the utility of the rabbit as a nonclinical species for ocular biologic therapeutics" [Regul. Toxicol. Pharmacol. (2017) 221-230].
Christina L Zuch de Zafra, Vito G Sasseville, Steven Matsumoto, Christian Freichel, Mark Milton, Timothy K MacLachlan

Regul Toxicol Pharmacol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges and opportunities for the future of monoclonal antibody development: Improving safety assessment and reducing animal use.
Fiona Sewell, Kathryn Chapman, Jessica Couch, Maggie Dempster, Shawn Heidel, Timothy K Maclachlan

MAbs· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inflammation and immunogenicity limit the utility of the rabbit as a nonclinical species for ocular biologic therapeutics.
Christina L Zuch de Zafra, Vito G Sasseville, Steven Matsumoto, Christian Freichel, Mark Milton, Timothy K MacLachlan

Regul Toxicol Pharmacol· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Derisking Drug-Induced Carcinogenicity for Novel Therapeutics.
Jonathan G Moggs, Timothy MacLachlan, Hans-Joerg Martus, Philip Bentley

Trends Cancer· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Not reinventing the wheel: applying the 3Rs concepts to viral vector gene therapy biodistribution studies.
Timothy K MacLachlan, Maritza McIntyre, Kyriacos Mitrophanous, James Miskin, Douglas J Jolly

Hum Gene Ther Clin Dev· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Storm forecasting: additional lessons from the CD28 superagonist TGN1412 trial.
Christopher Horvath, Laura Andrews, Andreas Baumann, Lauren Black, Diann Blanset, Timothy K MacLachlan

Nat Rev Immunol· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nonclinical evaluation of GMA161--an antihuman CD16 (FcγRIII) monoclonal antibody for treatment of autoimmune disorders in CD16 transgenic mice.
Meghan M Flaherty, Timothy K MacLachlan, Misty Troutt, Tomas Magee, Nadine Tuaillon

Toxicol Sci· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of choroidal neovascularization in a nonhuman primate model by intravitreal administration of an AAV2 vector expressing a novel anti-VEGF molecule.
Michael Lukason, Elizabeth DuFresne, Hillard Rubin, Peter Pechan, Qiuhong Li, Timothy Maclachlan

Mol Ther· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical safety evaluation of AAV2-sFLT01- a gene therapy for age-related macular degeneration.
Timothy K Maclachlan, Michael Lukason, Margaret Collins, Robert Munger, Elisabete Isenberger

Mol Ther· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vino, curationis?
Timothy K MacLachlan

Cancer Biol Ther· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Insulin-like growth factor factor binding protein-2 is a novel mediator of p53 inhibition of insulin-like growth factor signaling.
Adda Grimberg, Carrie M Coleman, Zonggao Shi, Timothy F Burns, Timothy K MacLachlan

Cancer Biol Ther· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Marine-derived cancer therapeutics making a splash.
Timothy K MacLachlan, Jan Pinkas

Cancer Biol Ther· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Insights into differential endostatin activity.
Timothy K Maclachlan, Mohanraj Dhanabal

Cancer Biol Ther· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of DNA-binding of tumor suppressor genes by chromatin immunoprecipitation.
Timothy K MacLachlan, Wafik S El-Deiry

Methods Mol Biol· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of cyclin-dependent kinase activity.
Timothy K MacLachlan, Wafik S El-Deiry

Methods Mol Biol· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BRCA1 augments transcription by the NF-kappaB transcription factor by binding to the Rel domain of the p65/RelA subunit.
Miriam Benezra, Nathalie Chevallier, Debra J Morrison, Timothy K MacLachlan, Wafik S El-Deiry

J Biol Chem· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-based design of p18INK4c proteins with increased thermodynamic stability and cell cycle inhibitory activity.
Ravichandran N Venkataramani, Timothy K MacLachlan, Xiaomei Chai, Wafik S El-Deiry, Ronen Marmorstein

J Biol Chem· December 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis